This Code of Conduct is the first step to showing dedication to upholding continuous excellence in both business and ethical terms, and showing our care and dedication to products, clients and success.
Code of conduct
- Published:
- written by: Polpharma Biologics
Related news
Other news related to this topic that may be of interest to you
Polpharma Biologics confirms U.S. launch of Tyruko® (natalizumab), the first and only biosimilar for Multiple Sclerosis
November 17, 2025 – Polpharma Biologics, a biopharmaceutical company group focused on biosimilars development...
Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar
Zurich, Switzerland – October 21, 2025 – Polpharma Biologics today announced Ranivisio® PFS (ranibizumab...
Polpharma Biologics is splitting its operations into two independent companies
Polpharma Biologics is splitting its operations into two independent companies, each with a clear focus...
Polpharma Biologics and MS Pharma sign licensing agreements for proposed vedolizumab (PB016), ocrelizumab (PB018) and guselkumab (PB019) biosimilars.
Amsterdam, Gdańsk – September 2nd, 2025 – Polpharma Biologics S.A. (“Polpharma Biologics”), specialized...